Home>Topics>>Investors Kick Chelsea After It Trips On Its Northera Data Again
Investors Kick Chelsea After It Trips On Its Northera Data Again
Healthcare Sector and Stocks Analysis from Seeking Alpha
Thu, 6 Dec 2012
By EP Vantage : Chelsea Therapeutics ( CHTP ) started 2012 as a fairly well-capitalised company as one-product groups working in CNS go, but will probably exit the year among the smallest of the small, and with little hope of getting the hypotension treatment Northera past U.S. regulators anytime ...
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.